• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.

作者信息

Guo Wancheng, Zhan Yihao, Mery David, Siegel Eric R, Sun Fumou, Cheng Yan, Ashby Timothy Cody, Zhang Zijun, Bailey Clyde, Alapat Daisy V, Peng Hongling, Hadidi Samer Al, Thanendrarajan Sharmilan, Schinke Carolina, Zangari Maurizio, van Rhee Frits, Tricot Guido, Shaughnessy John D, Zhan Fenghuang

机构信息

Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Department of Haematology, Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China.

出版信息

Blood Cancer J. 2024 Feb 14;14(1):30. doi: 10.1038/s41408-024-00998-9.

DOI:10.1038/s41408-024-00998-9
PMID:38355688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10866867/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e85b/10866867/d11390e5a320/41408_2024_998_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e85b/10866867/331931dd3cfd/41408_2024_998_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e85b/10866867/d11390e5a320/41408_2024_998_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e85b/10866867/331931dd3cfd/41408_2024_998_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e85b/10866867/d11390e5a320/41408_2024_998_Fig2_HTML.jpg

相似文献

1
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.铁蛋白在自体造血干细胞移植的多发性骨髓瘤患者中的预后价值：与基因表达谱模型和国际分期系统的整合
Blood Cancer J. 2024 Feb 14;14(1):30. doi: 10.1038/s41408-024-00998-9.
2
Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation.半定量 FDG 参数可预测无自体干细胞移植的多发性骨髓瘤患者的生存情况。
Cancer Imaging. 2023 Oct 27;23(1):104. doi: 10.1186/s40644-023-00625-z.
3
Does ferritin level affect the outcomes of autologous stem cell transplantation equally in all diseases?铁蛋白水平是否会在所有疾病中对自体干细胞移植的结果产生同等影响？
Transfus Apher Sci. 2023 Jun;62(3):103655. doi: 10.1016/j.transci.2023.103655. Epub 2023 Feb 16.
4
Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.回顾性分析自体造血干细胞移植治疗多发性骨髓瘤的疗效及影响因素。
Artif Organs. 2019 Oct;43(10):1028-1034. doi: 10.1111/aor.13468. Epub 2019 May 20.
5
Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.免疫调节剂药物/蛋白酶体抑制剂时代自体干细胞移植后多发性骨髓瘤患者预后因素的变化趋势
Cancer Sci. 2015 Feb;106(2):179-85. doi: 10.1111/cas.12594. Epub 2015 Feb 6.
6
[Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].自体造血干细胞移植后多发性骨髓瘤的长期随访：单中心结果
Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):499-504. doi: 10.3760/cma.j.issn.0253-2727.2017.06.007.
7
Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine.多发性骨髓瘤患者在新药时代接受自体移植治疗后生存率提高。
Cancer Sci. 2021 Dec;112(12):5034-5045. doi: 10.1111/cas.15163. Epub 2021 Oct 26.
8
Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.自体移植后生存的预后因素：133例多发性骨髓瘤患者的单中心经验
Bone Marrow Transplant. 2005 Jan;35(2):159-64. doi: 10.1038/sj.bmt.1704728.
9
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.新型药物时代自体造血干细胞移植后多发性骨髓瘤早期复发的预后列线图。
Cancer Med. 2023 Apr;12(8):9085-9096. doi: 10.1002/cam4.5630. Epub 2023 Apr 6.
10
Prognostic value of the second revision of the international staging system (R2-ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.国际分期系统第二次修订版（R2-ISS）在接受自体造血干细胞移植的多发性骨髓瘤患者中的预后价值。
Hematol Oncol. 2024 Jan;42(1):e3248. doi: 10.1002/hon.3248.

引用本文的文献

1
An Artificial Intelligence Pipeline for Hepatocellular Carcinoma: From Data to Treatment Recommendations.一种用于肝细胞癌的人工智能流程：从数据到治疗建议
Int J Gen Med. 2025 Jul 2;18:3581-3595. doi: 10.2147/IJGM.S529322. eCollection 2025.
2
Prognostic significance of baseline serum ferritin in newly diagnosed multiple myeloma cases: A retrospective study from southern India.新诊断多发性骨髓瘤患者基线血清铁蛋白的预后意义：一项来自印度南部的回顾性研究。
Indian J Med Res. 2025 Mar;161(3):306-314. doi: 10.25259/IJMR_1065_2024.
3
Effect of tandem autologous stem cell transplantation on survival in pediatric patients with high-risk solid tumors in South China.

本文引用的文献

1
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.修订版国际分期系统（R2-ISS）在多发性骨髓瘤整体生存中的应用：Harmony 项目下欧洲骨髓瘤网络（EMN）的报告。
J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
2
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
3
串联自体干细胞移植对中国南方高危实体瘤儿科患者生存的影响。
World J Stem Cells. 2025 Feb 26;17(2):100621. doi: 10.4252/wjsc.v17.i2.100621.
4
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.血红素通过MEK-ERK信号传导和嘌呤生物合成促进多发性骨髓瘤对维奈托克耐药。
Blood. 2025 Feb 13;145(7):732-747. doi: 10.1182/blood.2024025690.
[Survival prognosis factors in multiple myeloma].
[多发性骨髓瘤的生存预后因素]
Tunis Med. 2014 Jun;92(6):399-405.
4
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.硼替佐米与地塞米松治疗多发性骨髓瘤：谷草转氨酶（AST）和乳酸脱氢酶（LDH）水平升高与总生存期预后较差相关。
BMC Cancer. 2014 Jun 21;14:462. doi: 10.1186/1471-2407-14-462.
5
International staging system for multiple myeloma.多发性骨髓瘤国际分期系统
J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4.
6
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
J Clin Oncol. 1997 Jul;15(7):2659-66. doi: 10.1200/JCO.1997.15.7.2659.
7
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.多发性骨髓瘤的不良预后仅与13号染色体的部分或完全缺失或涉及11q的异常有关，而与其他核型异常无关。
Blood. 1995 Dec 1;86(11):4250-6.
8
Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.第三届医学研究委员会骨髓瘤试验的预后特征。医学研究委员会成人白血病工作组。
Br J Cancer. 1980 Dec;42(6):831-40. doi: 10.1038/bjc.1980.330.
9
A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.
Blood. 1980 Jun;55(6):1011-9.
10
Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients.浆细胞骨髓瘤。112例患者生存与各种临床表现及异常蛋白类型关系的研究。
Am J Med. 1967 Jun;42(6):937-48. doi: 10.1016/0002-9343(67)90074-5.